Douglas J. Swirsky net worth and biography

Douglas Swirsky Biography and Net Worth

CFO of MaxCyte

Mr. Swirsky is a seasoned financial leader with more than 20 years of experience in the healthcare sector, including as a public company executive at Nasdaq-listed organizations. He previously held various executive leadership positions at several biotechnology companies including AavantiBio, Rexahn Pharmaceuticals and GenVec. He also worked in the investment banking industry at Stifel Nicolaus, Morgan Stanley, UBS, PaineWebber and Legg Mason. He currently serves as the Chairman of the Board of Cellectar Biosciences.

Mr. Swirsky is a certified public accountant and CFA^® charterholder. He received a Master of Business Administration from the Kellogg School of Management at Northwestern University in Chicago and a Bachelor of Science in business administration from Boston University.

What is Douglas J. Swirsky's net worth?: The estimated net worth of Douglas J. Swirsky is at least $102.56 thousand as of March 17th, 2026. Mr. Swirsky owns 151,669 shares of MaxCyte stock worth more than $102,559 as of March 31st. This net worth approximation does not reflect any other investments that Mr. Swirsky may own. Learn More about Douglas J. Swirsky's net worth.
How do I contact Douglas J. Swirsky?: The corporate mailing address for Mr. Swirsky and other MaxCyte executives is 22 FIRSTFIELD ROAD SUITE 110, GAITHERSBURG MD, 20878. MaxCyte can also be reached via phone at 301-944-1700 and via email at [email protected]. Learn More on Douglas J. Swirsky's contact information.
Has Douglas J. Swirsky been buying or selling shares of MaxCyte?: During the past quarter, Douglas J. Swirsky has sold $8,215.02 in shares of MaxCyte stock. Most recently, Douglas J. Swirsky sold 10,142 shares of the business's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $0.81, for a transaction totalling $8,215.02. Following the completion of the sale, the chief financial officer now directly owns 151,669 shares of the company's stock, valued at $122,851.89. Learn More on Douglas J. Swirsky's trading history.
Who are MaxCyte's active insiders?: MaxCyte's insider roster includes Douglas Doerfler (Founder), Douglas Doerfler (Founder), Stanley Erck (Director), John Johnston (Director), Maher Masoud (CEO), David Sandoval (Senior Vice President and General Counsel), Ali Soleymannezhad (Insider), and Douglas Swirsky (CFO). Learn More on MaxCyte's active insiders.
Are insiders buying or selling shares of MaxCyte?: In the last year, MaxCyte insiders bought shares 5 times. They purchased a total of 355,000 shares worth more than $479,950.00. In the last year, insiders at the sold shares 2 times. They sold a total of 20,826 shares worth more than $30,544.58. The most recent insider tranaction occured on March, 17th when CFO Douglas J Swirsky sold 10,142 shares worth more than $8,215.02. Insiders at MaxCyte own 3.3% of the company. Learn More about insider trades at MaxCyte.
Information on this page was last updated on 3/17/2026.

Douglas J. Swirsky Insider Trading History at MaxCyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/17/2026	Sell	10,142	$0.81	$8,215.02	151,669
8/13/2025	Buy	50,000	$1.29	$64,500.00	161,811
3/18/2025	Sell	6,939	$3.18	$22,066.02	111,811

Douglas J. Swirsky Buying and Selling Activity at MaxCyte

MaxCyte Company Overview

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Today's Range

Now: $0.67

$0.66

$0.70

50 Day Range

MA: $0.83

$0.68

$1.25

2 Week Range

Now: $0.67

$0.64

$2.96

Volume

173,274 shs

Average Volume

1,116,814 shs

Market Capitalization

$71.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22